A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Study of Encorafenib + Binimetinib in Patients wit hBRAFV600-Mutant Melanoma Brain Metastasis
Sponsor: Array BioPharma Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS3457
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine if high-dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600. The time frame for the study is approximately 2 years.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a BRAFV600 mutation? Yes No
Do you have melanoma brain metastases? Yes No
Are you able to provide a tissue and blood sample? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE